Maneuvre

Maneuvre

Bedrijfsconsulting en -services

PR & communication advisory for visionary companies.

Over ons

Maneuvre is a boutique firm working with visionary companies and founders on PR, communications and growth. We help companies (including startups at the pre-seed through Series C level) access PR support at a price point that empowers them to scale. With offices in Amsterdam, Netherlands, and València, Spain, our hybrid team supports companies all over the world with their executive positioning, online presence, media relations, and more.

Website
http://maneuvre.co
Branche
Bedrijfsconsulting en -services
Bedrijfsgrootte
2-10 medewerkers
Hoofdkantoor
Amsterdam
Type
Particuliere onderneming
Opgericht
2020
Specialismen
PR, Public Relations, Communications, Web3, Emerging Technology, AI, Biotech, Longevity, Agritech, Fintech, Payments en Blockchain

Locaties

Medewerkers van Maneuvre

Updates

  • Organisatiepagina weergeven voor Maneuvre, afbeelding

    348 volgers

    When launching a startup, it's common for the brand narrative to take shape over time. In those early stages, knowing what to focus on and how to build a compelling story can make all the difference in setting your brand apart. That’s where The Ultimate Founders Guide to PR comes in. Created by our expert team at Maneuvre, the book is filled with practical insights tailored specifically for founders ready to make an impact, willing to learn what they should require from a PR agency, and how to prepare for their first announcement. For a limited time, when you get your copy, you’ll also enjoy a private 30-minute Q&A with Rachel P.. This is a great opportunity to ask your burning questions and receive personalised insights. No matter where you are in your PR journey, this book will help you: ✨ Build a strong foundation for your PR efforts that aligns with your mission. ✨ Connect with more media and effectively communicate your narrative to stand out. ✨ Position yourself as a thought leader in your industry, fostering relationships that matter. Interested? Check more here 👉 https://lnkd.in/d_-gcgPd

    • Geen alternatieve tekst opgegeven voor deze afbeelding
  • Organisatiepagina weergeven voor Maneuvre, afbeelding

    348 volgers

    With so many events throughout the year, it's impossible to attend them all, but Web Summit is a must if you want to understand what’s happening right now and what’s coming next. So, how can you make sure you’re getting the best return on investment from the event? 📅 Plan your schedule: With so many stages and speakers, it’s easy to get overwhelmed. Highlight the key sessions that align with your goals or feature people you’d like to meet. 👋 Network with intent: You’ll meet people everywhere – from the conference floor to the coffee line. Be intentional about who you want to connect with. Don’t overlook side events either—some of the most valuable conversations happen away from the main stages. 📲 Use the app: Leverage the Web Summit app to build your connections list in advance, so you’re not scrambling during the event. And, of course, we’ll be there too – so if you want to chat, connect with Michalina Brokos 🔜 Web Summit / Lisbon and Andrea Gomez Lopez!

    • Geen alternatieve tekst opgegeven voor deze afbeelding
  • Organisatiepagina weergeven voor Maneuvre, afbeelding

    348 volgers

    There are two reasons founders and execs don’t post more online (whether their own writing or on LinkedIn). One, they don’t want to brag and turn off their customers/investors. Two, they don’t want to give away info that their competitors could use. The good news is that you and your team can show up as experts without doing either. 🥸 Here’s a good example: Premo Ojokojo from AZA Finance addresses the challenges and solutions for building diverse teams in the fintech space. Achieving high team retention or gender parity in this industry is not easy, but the AZA Finance team has been very successful in this area—and Premo was happy to share her tips with other HR directors. You can read Premo’s op-ed in theHRDIRECTOR here: https://lnkd.in/dnuPhisG.

    How to build a diverse team that stays with your fintech for years

    How to build a diverse team that stays with your fintech for years

    https://www.thehrdirector.com

  • Organisatiepagina weergeven voor Maneuvre, afbeelding

    348 volgers

    In today's fast-paced digital world, timing is everything. Major industry events gather the brightest minds, biggest brands, and most disruptive startups in one place. They also gather many of your possible investors, clients, or partners. With so much innovation and activity concentrated in a few days, the window of opportunity to make a splash is both exciting and narrow. Brands that announce during these key moments can get unparalleled exposure—but only if they do it right. Big events (like Web Summit, which is already next month 👀) provide a huge platform to get your message out there, but with so many companies fighting for attention, you’ll need a solid strategy to stand out: ⏱️ Timing is everything. Are you speaking at one of the panels or giving the keynote? Is it possible to mention your announcement there? Maybe you should organise a small side event during the conference? Big events sometimes offer assistance with announcements—look for insights on their website, in a media pack, or in other guidelines you received. 🎉 Clarity & visibility – your message needs to stand out, especially when so much else is happening. Media exclusives can help create excitement and ensure you reach your core audience. If you know what you’re announcing and when you want to do it, already start reaching out to journalists. And remember: the story is exclusive. So you offer it exclusively to one journalist at a time. 📤 Outreach – prep your media and outreach strategy ahead of time so you’re not too stressed with it at the last minute. If you’re not announcing your news exclusively, it’s a good idea to send it to the journalists under embargo to give them some time to prep the article (they may not have enough time to do it if they’re also attending the conference!) There’s still time to get it right. Need some help? Contact us @ [email protected]. PS: Check the Web Summit schedule here: https://lnkd.in/eKixThgs

    Schedule | Web Summit | November 11-14, 2024

    Schedule | Web Summit | November 11-14, 2024

    websummit.com

  • Organisatiepagina weergeven voor Maneuvre, afbeelding

    348 volgers

    One impressive statistic. That's all your company really needs to stand out. A single, verifiable, non-skewed data point that shows: 🔎 Why you, why now, and why someone who isn't financially incentivised to support you (such as your regulators, or the press) should care. Then, once you have it, share it - with visuals! Even better is to collect several data points and publish them all, proudly, just like Solynta | true potato seeds has done here in their latest Kenya report. They have the numbers to prove that, indeed, they *are* helping farmers use less fungicide, meaning these growers can achieve ESG goals and still provide enough food for our global nutrition security. This is a great example of how to capture your wins in a way that is newsworthy and easily understandable. https://lnkd.in/exH6EdfV

    • Geen alternatieve tekst opgegeven voor deze afbeelding
  • Organisatiepagina weergeven voor Maneuvre, afbeelding

    348 volgers

    Your less-than-perfect-but-entirely-your-own-expertise writing > anything ChatGPT creates for you. This is true for all of us, but especially true if you work in emerging technologies. Why? 🤔 There’s not as much for AI to ‘learn from’ if your work is truly bleeding-edge-new. It’s never going to get your novel tech just right. and 🤔 If you are bleeding-edge-new, you have the opportunity to define, early on, what makes your tech great - if you delegate this to a non-expert, it’s just not going to be expertise. It’s going to be words. Therefore, please, if you do nothing else: Don’t send AI op-eds or answers to press. First of all, they will know - and will know you as someone that didn’t take the time. Second, their job is to take your expertise and, after vetting it, share it in a digestible way to their readers (your investors, clients, communities). For that trade to work, you have to provide something original. Thanks for the inspiration Stefano De Marzo!

    Profiel weergeven voor Stefano De Marzo, afbeelding

    Journalist & Editor

    AI writing is like those WordArt options from the 90s 💻🧑🎨 The thing is I believe AI will make human writing even more valuable. Being a journalist, when ChatGPT came out, I was in denial. I didn’t want to hear about it. After some months I tried it out and I was impressed. However, soon enough that excitement wore off. Back in those days, I came up with this theory that I shared with colleagues: AI will make human writing even more valuable. Crazy, because at first, everybody thought it was gonna replace writers and editors (probably it has to some extent). But another consequence of this has been to realise how scarce good writing is. By now it’s easy to spot AI-generated content (even without the help of AI detectors). Something is missing there in those texts. In a way, writing has been commoditised by AI, and for that same reason, we can identify the good from the bad. I cannot help but think that AI writing is like those WordArt options from the 90s Microsoft Word, as I said at the beginning. I think media is slowly going back to basics, good reporting, good writing and, maybe, print. 

    • Geen alternatieve tekst opgegeven voor deze afbeelding
  • Organisatiepagina weergeven voor Maneuvre, afbeelding

    348 volgers

    If you want to get a speaking slot at the event, start appearing in podcasts, have your op-ed placed, or start being recognised as an important voice in your industry, there are several things you can do. And they can be summarised in this short sentence: be active. 💡 Be active on social media: Share that article that recently got you inspired/made you think about something specific. Or write a piece sharing your expertise and publish it on your LinkedIn. 👋 Be active at networking events and conferences: Take the opportunity to connect with people and build your exposure and position. 📰 Be active with media opportunities: If a journalist is seeking an expert to comment on a topic within your expertise, reach out and share your opinion or connect them with someone else in your network who can be helpful. These things pay off. They will come back to you in a good sense sooner or later. Like this week for LongeVC’s Artem A. Trotsyuk, who shared a commentary for an in-depth, well-researched article on AI in a biotech bubble by Jules ADAM from Labiotech.eu. This is definitely a piece you want to be featured in as an industry expert. If you're interested in the future of AI and biotech and appreciate good journalism, make sure to give it a read: https://lnkd.in/dhHqe2yK

    Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration

    Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration

    https://www.labiotech.eu

  • Organisatiepagina weergeven voor Maneuvre, afbeelding

    348 volgers

    When you're a B2B startup, the people that most need your tech probably don't read the news you do - and that's normal! To find them, you need to take your story on the road. Before you do that, though, make sure you are ready to answer these three questions: 1. What evidence do you have (real world evidence!) that your technology works in that sector? Think use cases, customer partnerships, etc. 2. Who at your company has credibility with this audience? In other words: Who is sharing this evidence, and are they trustworthy? Can they speak with authority and will their perspective be trusted? 3. What does your tech do again? Be ready to explain it, and explain it again! With these answers in hand, you should have what editors want, what readers expect, and what your future possible partners care about. And if that happens to be better provenance of data, including for clinical trials, we recommend giving this great piece from Clinical Leader a read! Federico Turkheimer from King's College London and Eric Wragge from the Algorand Foundation discussed how blockchain can ensure data integrity and provenance in scientific research. You can read the full article here: https://lnkd.in/dBfTAZPS

    Is Blockchain The Solution To Derisking Unreliable Clinical Trial Data?

    Is Blockchain The Solution To Derisking Unreliable Clinical Trial Data?

    clinicalleader.com

  • Organisatiepagina weergeven voor Maneuvre, afbeelding

    348 volgers

    If you want a model for how to be on LinkedIn, here it is! There’s a lot of ‘spam’ here nowadays, and if you’ve been told just ‘to post regularly’, it’s easier to just reshare something, or churn out a quick “I’m thrilled…” post. Especially if you’re busy (looking at you, company founders/CEOs). It is important to stay active, but it’s more important to bring value! Share a piece of your knowledge - a few sentences is more than enough. Do it regularly, and you’ll have the presence and engagement that makes you more noticeable to event organizers, journalists, and partners. And if you need some inspiration, go take a look at Garri Zmudze. One last piece of advice: open your calendar and book 30 minutes each week to do some LinkedIn-ing. It can be sharing the last interesting newsletter/book/report/podcast you checked or simply reposting other content that resonates with you. It's a good start!

    Profiel weergeven voor Garri Zmudze, afbeelding

    Longevity and biotech VC

    In a recent report “Biotech financing: darkest before the dawn” by Melanie Senior published in Nature Biotechnology, she examines the biotech sector's financial landscape in detail, offering insights into the challenges and emerging opportunities in 2024. Here are some key takeaways from the report: ✔ Modality matters. Antibody-drug conjugates (ADCs) and radioligand therapies (RLTs) are gaining significant investor interest, with companies like Tubulis and Pheon Therapeutics raising $139 million and $120 million, respectively, to advance their cancer-focused ADCs. Meanwhile, cell and gene therapy (CGT) companies are struggling, with venture funding, the number of financings, and average round sizes all down sharply in 2024. ✔ Investment trends are showing a clear preference for later-stage programs. The average Series A round in 2024 is $80 million, more than double the $40 million average in 2019. So far this year, a quarter of all Series A rounds have been over $100 million. The trend towards fewer but larger funding rounds is evident, with at least 50 companies raising rounds worth $100 million or more in 2024. ✔ Artificial intelligence (AI) and machine learning continue to attract significant venture capital. Companies in this space are on track to raise more funding in 2024 than in any previous year, except for the peak in 2021. For example, Xaira Therapeutics raised a record-breaking $1 billion in a Series A round, the largest initial funding commitment in Arch Venture Partners' history. ✔ Corporate venture capital (VC) is increasingly stepping in to support early-stage innovation, particularly in Europe. In the first half of 2024, European biopharma and platform firms raised $2.2 billion, putting the region on track to surpass all years except 2021. Notable investments include Disco Pharmaceuticals' $21.5 million seed round, led by corporate VCs like M Ventures and AbbVie Ventures. ✔ The biotech sector is experiencing a bifurcation. While companies with later-stage clinical assets are attracting large rounds of funding, early-stage companies without proof-of-concept data face significant challenges. Valuation corrections are occurring, particularly for those seeking Series B or C funding, with many companies forced to accept lower valuations than during the pandemic-driven boom. ✔ Despite facing challenges similar to its Western counterparts, including muted IPOs and a broader economic downturn, China remains a "reservoir of opportunity" for investors. The quality of Chinese biotech assets is improving, yet they remain undervalued compared to U.S. counterparts. If you are building a startup in aging/biotech, reach out to our team at LongeVC #venturecapital #biotech #drugdiscovery Image source: Senior, M. Biotech financing: darkest before the dawn. Nat Biotechnol (2024).

    • Geen alternatieve tekst opgegeven voor deze afbeelding
  • Organisatiepagina weergeven voor Maneuvre, afbeelding

    348 volgers

    The world would be a sadder place without potatoes. Imagine how many amazing dishes from various cuisines would be incomplete. It's hard to imagine burgers without fries, isn't it? On a more serious note, potatoes play a crucial role in combating world hunger. They are healthy, fast-growing, and high-yielding. Surprisingly, they can also be grown from seeds, not just from tubers. If you haven’t heard about it, go and check all the work Solynta | true potato seeds is doing. Recently, three of their hybrid true potato seeds were given the green light for commercial release in Kenya. This means that Kenyan farmers now have the opportunity to grow their potatoes from Solynta’s seeds, leading to water and energy savings, increased yields, and effective measures against common potato diseases. Given Solynta's incredible work over the past two decades, it's safe to say that the Kenyan market is just the beginning of their journey. Read more below in the EU Reporter’s piece. And if you're keen on staying updated on the latest updates in the agritech sector, make sure to follow Food Innovation Online Corp (PotatoPro.com)Future FarmingLukie Pieterse from Potato News Today, Niels van der Boom from Farm Media and Boeren Business, Ben Payton from African Business Magazine or Fresh Produce Middle East & Africa Magazine. Can’t wait to be able to buy and grow potatoes from your seeds in Europe, Solynta | true potato seeds! Once again, congrats to Caroline Elias-Mackay, Charles Miller, Joost van Regteren, and the whole team. https://lnkd.in/dY2kT7rx

    Solynta’s hybrid true potato seed varieties approved for commercial release in Kenya - EU Reporter

    Solynta’s hybrid true potato seed varieties approved for commercial release in Kenya - EU Reporter

    https://www.eureporter.co

Vergelijkbare pagina’s

Door vacatures bladeren